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Properdin and factor H are two key regulatory proteins having opposite functions in the
alternative complement pathway. Properdin up-regulates the alternative pathway by sta-
bilizing the C3bBb complex, whereas factor H downregulates the pathway by promoting
proteolytic degradation of C3b. While factor H is mainly produced in the liver, there are
several extrahepatic sources. In addition to the liver, factor H is also synthesized in fetal
tubuli, keratinocytes, skin fibroblasts, ocular tissue, adipose tissue, brain, lungs, heart,
spleen, pancreas, kidney, muscle, and placenta. Neutrophils are the major source of prop-
erdin, and it is also produced by monocytes, T cells and bone marrow progenitor cell line.
Properdin is released by neutrophils from intracellular stores following stimulation by N -
formyl-methionine-leucine-phenylalanine (fMLP) and tumor necrosis factor alpha (TNF-α).
The HEP G2 cells derived from human liver has been found to produce functional properdin.
Endothelial cells also produce properdin when induced by shear stress, thus is a physio-
logical source for plasma properdin.The diverse range of extrahepatic sites for synthesis of
these two complement regulators suggests the importance and need for local availability
of the proteins. Here, we discuss the significance of the local synthesis of properdin and
factor H. This assumes greater importance in view of recently identified unexpected and
novel roles of properdin and factor H that are potentially independent of their involvement
in complement regulation.
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INTRODUCTION
The complement system consists of various plasma proteins that
circulate in the serum, such as zymogens, which upon stimula-
tion interact with each other to opsonize pathogens and pro-
mote their removal by phagocytosis. Complement activation takes
place via three pathways – classical, lectin, and alternative path-
ways. The classical pathway is activated when its recognition
component C1 binds to a target, via C1q. C1q recognizes tar-
gets mainly by surface charged clusters, and binds directly to
many bacteria, apoptotic cells, or surfaces which have IgG or IgM
attached (Kishore and Reid, 1999; Arlaud and Thielens, 2010).
The complement protein complex C1 is made up of three pro-
teins, C1q, C1r, and C1s. Upon binding of the C1q protein to
Abbreviations: AP, alternative pathway; CCP, complement control protein;
DCs, dendritic cells; DDD, dense deposit disease; ECs, endothelial cells; FHbp,
factor H binding protein; fMLP, N -formyl-methionine-leucine-phenylalanine;
HUVECs, human umbilical vein endothelial cells; IFN-γ, Interferon-gamma; IL-
1α, interleukin-1 alpha; IL-1β, Interleukin-1 beta; IL-2, interleukin 2; IL-8, inter-
leukin 8; LOS, lipooligosaccharide; LPS, lipopolysaccharides; MAC, membrane
attack complex; MSCs, mesenchymal stem cells; NspA, Neisserial surface protein
A; PBMCs, peripheral blood mononuclear cells; PMA, phorbol 12-myristate 13-
acetate; TGF-ß1, transforming growth factor-ß1; TNF-α, tumor necrosis factor
alpha.
a target, C1r and C1s, which are protease zymogens, become
activated and C1s cleaves the C4 and C2 complement compo-
nents. C4 is cleaved into C4a and C4b. C4a is an anaphylatoxin
that causes inflammation and C4b attaches to the target sur-
face. C1s cleaves C2 into C2a and C2b, resulting in the forma-
tion of C3 convertase C4bC2a, which generates C3b by cleaving
C3. Subsequently, C5 convertase (C4b2a3b) is formed result-
ing in the formation of the membrane attack complex (MAC)
and lysis (Kishore and Reid, 1999; Fujita, 2002; Carroll and Sim,
2011).
The activation of the complement system via the lectin path-
way occurs as a result of carbohydrate and other moieties on
target surfaces being bound by mannose binding lectin (MBL),
ficolins, or collectin-11 (recognition subcomponents of the lectin
pathway) (Sim and Laich, 2000; Fujita, 2002; Cestari Idos et al.,
2009). These recognition proteins are associated with the protease
zymogens MBL-associated-serine-protease (MASP)-1, MASP-2,
MASP-3, which are orthologs of C1r and C1s. MASP-2, like C1s,
functions to cleave C4 into C4a and C4b and C2 into C2a and C2b.
Similar to the classical pathway, a C3 convertase complex, C4b2a
is formed leading to the generation of C5 convertase (C4b2a3b),
which also leads to the formation of the MAC (Fujita, 2002; Carroll
and Sim, 2011).
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The activation of alternative pathway takes place on various
cellular surfaces such as yeasts, bacteria, and parasites, and is also
stimulated by antibody-antigen complexes consisting of IgG or
IgA (Carroll and Sim, 2011). Recently, mice studies suggested that
MASP-3 is involved in the activation of the alternative pathway.
The study demonstrated that the activation of the alternative path-
way was restored by the addition of recombinant MASP-3, in sera
from MASP or MASP/C4 gene deficient mice. This signifies that
MASP-3 may be an important protease required for alternative
complement pathway (Iwaki et al., 2011).
Properdin and factor H are key regulatory proteins of the alter-
native pathway (Kemper and Hourcade, 2008). The initiation of
the alternative pathway is triggered by a conformational change
in C3 cleaved at a single site by the serine protease C3 convertase
(Carroll and Sim, 2011). This leads to the generation of C3a, an
anaphylatoxin, and C3b. Nascent C3b binds covalently to surfaces
(e.g., of bacterial or fungal cells) through a reactive thioester moi-
ety. Factor B (a protease zymogen) can then associate with C3b in
the presence of Mg2+. Once the C3bB complex has formed factor
D, a serine protease, cleaves factor B into Ba and Bb fragments.
The Bb fragment remains bound to C3b generating the C3 con-
vertase C3bBb of the alternative pathway. C3bBb is not very stable
under physiological conditions and has half life of about 90 s. This
complex is stabilized by binding of properdin (to form C3bBbP),
which increases its half life by 5–10-fold (Pillemer et al., 1954; Le
et al., 2007). In this amplification loop, further C3b molecules are
generated, which are deposited adjacent to the convertase leading
to opsonization and the formation of C5 convertase, cleaving C5
into C5a and C5b. This leads to the lytic pathway and cell lysis.
On the other hand, the activation cascade is downregulated on
host cells due to control by membrane-bound regulatory proteins,
factor H, and factor I. Human factor H inhibits the C3 conver-
tase formation by binding to C3b. Together with factor I, factor H
cleaves C3b to iC3b. In addition it increases the convertase decay
activity, thus inhibiting the activation of complement alternative
pathway (Sim et al., 1993).
PROPERDIN STRUCTURE AND FUNCTION
Properdin is a soluble glycoprotein found in plasma at a concen-
tration of about 25µg/ml composed of several identical subunits
of 53 kDa binding to each other in a head to tail manner (Dis-
cipio, 1982; Nolan et al., 1992) to form cyclic polymers (dimers,
trimers, and tetramers) distributed in plasma in a ratio of 26:54:20
(Smith et al., 1984). The monomer is a flexible rod-like structure
with a length of 26 nm and a diameter of 2.5 nm The human
properdin monomer is 442 amino acids long and is composed
of six (or seven, see below) non-identical tandem repeats of
about 60 amino acids called thrombospondin type I (TSR) repeats
(Goundis and Reid, 1988; Higgins et al., 1995) TSRs are also found
in cell adhesion molecules in human blood platelets called throm-
bospondins. Initially each monomer of properdin was thought
to have five and a half TSR domains, each having 58–67 residues
with an addition of N-terminal and C-terminal domains (Sun
et al., 2004). However, further sequence alignments indicated that
there is a sixth TSR domain which is larger than the rest due to
a sequence insertion. More recent work proposes that properdin
has seven thrombospondin type I repeats instead of the six, as the
N-terminal domain (TSR-0, a truncated domain) has the same
six conserved Cys residues established in TSR1–TSR6 (Sun et al.,
2004) (Figure 1A).
The human properdin gene has 10 exons with a length of ∼
6 kb (Nolan et al., 1992). The first exon is untranslated, the sec-
ond exon consists of the translation start site as well as a sequence
which encodes 24 amino acids of signal peptide and the N-terminal
region is encoded by exon 3. Exon 4–8 encode each of the TSRs
1–5, exon 9 encodes the first 38 amino acids of TSR6 with the
remaining part of TSR6 encoded by exon 10 and the C-terminal
region is also encoded by exon 10 (Nolan et al., 1992; Higgins et al.,
1995).
Domain deletion studies (Higgins et al., 1995) have shown that
properdin lacking TSR4 forms dimers and binds to C3b, but not
to C3bBb. Properdin without TSR5 does not bind to C3b and so
for both deletions the C3bBb complex is not stabilized (Higgins
et al., 1995). Properdin lacking TSR3 is still able to form oligomers
(dimers, trimers, tetramers) and also monomers. This deletion
does not prevent properdin from binding C3b and the C3bBb
complex. TSR4 and TSR5, therefore, appear to play an impor-
tant role in the binding of C3b, sulfatides, and in the stabilization
of C3 convertase of the complement alternative pathway. TSR5 is
involved in the binding of sulfated glycoconjugates but the binding
region for C3bBb is different (Perdikoulis et al., 2001). Deletion
of TSR6 and the short C-terminal charged tail prevents the for-
mation of oligomers, and the monomers cannot stabilize C3bBb,
bind C3b, or sulfatide (Higgins et al., 1995).
Recent studies have shown that properdin (as well as factor H)
can recognize glycosaminoglycan (GAG), with properdin bind-
ing to more GAG epitopes than factor H, which requires sulfated
motifs on GAGs for interaction. These interactions by properdin
and factor H reported for renal tubular heparin sulfates involve
overlapping epitopes and can be modulated by anticoagulant
heparinoids (Zaferani et al., 2012). It has been demonstrated that
apoptotic T cell recognition by properdin is via GAG-binding site
(Kemper et al., 2008). Heparin interacts with properdin (and fac-
tor H) but the binding kinetics and dissociation constants (K d)
are dissimilar (Yu et al., 2005). Properdin has also been shown to
interact with sulfated glycoconjugates dextran sulfate and fucoidan
(Holt et al., 1990).
Though studies have shown interaction of properdin with
mammalian cells via GAGs, there are no GAGs present on Neisse-
ria or enteric bacteria, demonstrating that properdin also interacts
with other biochemical targets on microbial surfaces. Studies have
demonstrated the binding of properdin to Salmonella typhosa
lipopolysaccharide (LPS) and Neisseria meningitidis LOS induce
activation of the complement alternative pathway (Kimura et al.,
2008). Properdin has been reported to bind directly to microbial
surfaces, recruiting fluid phase C3b and so initiating the assem-
bly of the alternative pathway C3 convertase. Spitzer et al. (2007)
reported that properdin binds to wild-type Neisseria gonorrhoeae,
allowing the C3 convertase (C3bBbP) complex to form, which
leads to opsonization of bacteria. This suggests that properdin can
directly mediate the assembly of alternative pathway on microbial
surfaces (Spitzer et al., 2007) (Table 1). However it is possible that
unfractionated properdin undergoing freeze thawing consists of
high order oligomers of properdin, which may bind surfaces that
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FIGURE 1 | (A) Modular organization of thrombospondin repeats in
properdin. Properdin can be found in serum in different forms: monomers,
dimers, and trimers, tetramers. A molecule of properdin trimer is shown in
this figure along with the schematic representation of the MONOMER
with its TSRs. TSR0 is the N-terminal TSR. The brown rectangle on the end
of the TSR6 represents an N-glycosylation site. TSR4 has been shown to
be involved in the stabilization of the C3 convertase. TSR6 is involved in
the oligomerization of properdin monomers and TSR5 binds to C3b (figure
adapted from Sun et al., 2004 and data from Higgins et al., 1995). (B)
Illustration of a factor H molecule. Factor H has 20 CCP modules that
demonstrate different binding properties. The molecular structures for CCP
1–2, 2–3, 6–8, 10–11, 11–12, 13, 15–16, 19–20 have been established
experimentally. Human factor H decays Bb from C3b and is a cofactor for
degradation of C3b to iC3b by serine protease factor I. It attaches to
surface through its heparin/anionic binding sites in its carboxyl-terminus of
short complement repeats (CCP 16–20) while its decay-accelerating
activity and cofactor activity sites are at the amino-terminus (CCP 1–4)
(Based on Atkinson et al., 2007).
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Table 1 | Known functions of properdin.
Functions of properdin Reference
Properdin assembles C3bBb on a surface by promoting the association of C3b and factor B, and also binds C3 convertase Pillemer et al. (1954)
Binding of properdin to C3bBb complex allows it to be stabilized as it increases its half life of about 5–10-folds Hourcade (2006)
Direct binding of properdin to microbial organisms such as zymosan on yeast cell walls and N. gonorrhoeae results in
in situ assembly and function C3 convertases resulting in opsonization and elimination of pathogen
Pillemer et al. (1954)
Properdin binds to zymosan and this complex binds C3b. Spitzer et al. (2007)
Properdin also binds to erythrocytes, which leads to the generation of Er-C3bBbP complexes Cortes et al. (2011)
Properdin binds independently of C3b to late apoptotic cells and necrotic cells. This direct binding is crucial for the local
amplification of the complement alternative pathway activation.
Xu et al. (2008)
Properdin enhances apoptotic T cell uptake by macrophages and dendritic cells. Kemper et al. (2008)
native properdin would not (Farries et al., 1987). Agarwal et al.
(2010), however, found that properdin does not bind directly to
N. meningitidis or N. gonorrhoeae but enhances the deposition of
C3 on the bacterial surface by stabilizing the alternative pathway
C3 convertase. Another report has shown that native properdin
(dimer, trimer, tetramer) binds to Chlamydia pneumonia. The
binding of properdin to C. pneumonia increased C3b deposition
and induced complement activation (Cortes et al., 2011).
FACTOR H STRUCTURE AND FUNCTION
Human factor H is an extended glycoprotein (Sim and DiSci-
pio, 1982) of 155 kDa. It is thought to be mainly monomeric,
but may have some dimers in the circulating population (Perkins
et al., 2012). It consists of 20 complement control protein (CCP)
domains, each consisting of 60 amino acids (Ripoche et al., 1988a).
Human factor H contains three different binding sites for C3b or
C3d throughout its length with CCP 1–4 being the major site as
well as CCP 12–14 and CCP 19–20 (Alsenz et al., 1985; Gordon
et al., 1995; Jokiranta et al., 2000) (Figure 1B). The protein can
be found in the plasma at a concentration of ∼200–700µg/ml
(Kishore and Sim, 2012). Its main function is to distinguish
between endogenous and exogenous particles or surfaces and to
limit the activation of C3. Human factor H appears to bind mul-
tiple sites in C3 and has been shown to have a higher apparent
binding avidity for C3b bound to non-activators of the alternative
pathway compared to C3b bound to activators. This is thought
to occur because factor H binds to negative charge clusters such
as sialic acids or GAGs which cover mammalian cells, flagging
them as non-activators. Factor H can, therefore, bind to both the
polyanionic structures as well as C3b, resulting in a higher appar-
ent avidity for C3b bound to a non-activator surface (Meri and
Pangburn, 1990).
A number of proteins which are closely related in structure to
factor H, also circulate in plasma. These are factor H-like protein-1
(FHL-1) and factor H-related proteins 1–5 (FHR1-5) (Zipfel et al.,
2002). FHL-1 is also known as reconectin and consists only of
seven CCP domains followed by the amino acid sequence SFTL.
It arises as result of alternative splicing of the factor H gene. Its
CCP 1–7 are identical to those of factor H (Ripoche et al., 1988a).
FHRs 1–5, each of which is encoded by a separate gene in the
regulation of complement activation (RCA) cluster, have not been
functionally annotated fully, but FHR-3 and FHR-5 both bind C3b
and FHR-3 also binds heparin (Estaller et al., 1991; Hellwage et al.,
1999; McRae et al., 2001; Zipfel et al., 2002).
Human factor H functions as a downregulator of the alternative
pathway activation. It obstructs the formation of the alternative
pathway C3 convertase and enhances the decay of the conver-
tase (decay acceleration activity) by dissociating Bb from the C3
convertase complex and C5 convertase complex, thus inhibiting
the positive feedback loop (i.e., the amplified turnover of C3).
The formation of alternative pathway C3 convertase can also
be inhibited by the binding of factor H to C3b, hence inhibit-
ing the interaction of C3b and factor B (Sim et al., 1993). It
acts as a cofactor for factor I for the cleavage of C3b to iC3b
(cofactor activity). Mutations resulting to factor H functional
deficiency can cause uncontrolled alternative pathway activation,
as is the case in dense deposit disease (DDD) patients (Zhang
et al., 2012). Whereas human factor H functions to downreg-
ulate alternative pathway, properdin up-regulates by stabilizing
the C3 convertase, thus generating C3b molecules and leading
to opsonization and the formation of lytic pathway (Pangburn
and Muller-Eberhard, 1984) (Figures 2A,B). FHR4 demonstrates
qualitatively similar complement regulatory activity to factor H,
in both decay-accelerating and cofactor activities (Hellwage et al.,
1997).
Recently, factor H has been shown to directly compete with C1q
in binding to anionic phospholipids (e.g., cardiolipin) (Tan et al.,
2010), lipid A and Escherichia coli (Tan et al., 2011) and beta amy-
loid peptide (Nayak et al., 2010; Nayak et al., unpublished) and acts
as a direct downregulator of the classical pathway (Table 3). This
ability of factor H to dampen classical pathway activation is dis-
tinct from its role as an alternative pathway downregulator. Thus,
by directly competing with C1q to bind to self and non-self ligands
(Kishore et al., 2004), factor H is likely to be involved in regulating
C1q-mediated complement activation inflammatory processes in
autoimmunity and infection. It is interesting that factor H binds
to apoptotic cells, another C1q target, but has no effect on the
uptake of apoptotic cells by phagocytes. However, C1q-mediated
enhancement of uptake/adhesion of the apoptotic cells by mono-
cytes is considerably reduced by factor H (Kang et al., 2012). Thus,
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FIGURE 2 | Illustration of activities of factor H and properdin. (A)
Properdin can be found in serum in different forms: monomers, dimers, and
trimers. A Properdin stabilizes C3 convertase that cleaves more C3 to C3b
thus amplifying the process. (B) C3b bound on a surface can bind factor B.
C3b-factorB is cleaved by factor D to form C3bBb. Factor H can displace Bb
from its binding to C3b, and form a C3b-factor H complex. C3b-factor H is
cleaved by factor I to form iC3b; with the release of factor H, iC3b does not
bind factor B so cannot form a convertase like C3bBb.
factor H may be important in controlling the inflammation, which
might arise from C1q deposition on apoptotic cells.
A number of pathogens have acquired the ability to bind factor
H, via charge interactions (Lambris et al., 2008). N. meningitidis,
for example, has been shown to bind factor H probably to allow
the organism to evade the complement system. Two N. meningi-
tidis ligands, called factor H binding protein (FHbp) (Schneider
et al., 2009) and Neisserial surface protein A (NspA) (Madico et al.,
2006; Lewis et al., 2010, 2012) have been identified.
EXTRAHEPATIC BIOSYNTHESIS OF PROPERDIN
The majority of the complement pathway proteins are synthesized
in the liver. Extrahepatic biosynthesis of complement proteins
occurs in a wide variety of cells, e.g., in monocytes, fibroblasts, neu-
ronal cells, adipose tissue, and endothelial cells (EC) (Friese et al.,
1999). Properdin however, along with a few other complement
proteins, i.e., C1q, serine protease factor D and C7, have different
primary sources of synthesis. Neutrophils are the major source of
properdin. Monocytes, bone marrow progenitor cell lines and T
cells also produce properdin (Wirthmueller et al., 1997).
Human monocytes have been shown to secrete alternative path-
way complement proteins including properdin (Whaley, 1980).
The biosynthesis of properdin in response to LPS, phorbol 12-
myristate 13-acetate (PMA) and various cytokines has been
detected in the Mono-Mac-6 cell line, which has morphologically
and functionally similar to mature peripheral blood monocytes
(Schwaeble et al., 1994). TNF-α and IL-1ßenhance mRNA abun-
dance and secretion of properdin, whereas IFN-γ downregulates
it (Schwaeble et al., 1994).
PROPERDIN BIOSYNTHESIS BY DIFFERENT CELL TYPES
Maves and Weiler (1994) reported that functional properdin is
a product of human liver-derived HEP G2 cells. Although the
major extrahepatic source of properdin is neutrophils, the source
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Table 2 | Local (extra hepatic) biosynthesis of properdin.
Sites/source of biosynthesis of properdin Comments/possible implications Reference
Neutrophils Properdin is localized in the granules of neutrophils and released by TNF,
TNF/fMLP, PMA, C5a, or IL-8
Camous et al. (2011)
T cells Promotes phagocytosis of apoptotic T cells, suggesting that properdin
functions in the recognition and removal of apoptotic cells. Drives the
uptake of apoptotic cells by macrophages and dendritic cells.
Kemper and Hourcade (2008)
Endothelial cells Properdin up-regulation is induced by shear stress of 2–3 dyn/cm2 Bongrazio et al. (2003)
Peripheral blood monocytes Synthesize properdin, in vivo plays a crucial role in alternative pathway
mediated injury
Whaley (1980)
of properdin in circulation is not known. Human liver-derived
HEP G2 cells can produce functional properdin (Maves and Weiler,
1994). Properdin localized in the granules of human neutrophils
are secreted when stimulated with TNF, TNF/fMLP, PMA, C5a,
or IL-8. This suggests that neutrophils can promote complement
activation upon stimulation with cytokines or coagulation-derived
factor, thus stabilizing and amplifying the alternative pathway via
release of properdin. This allows the activation of the alterna-
tive pathway leading to defense against invading microorganisms
(Wirthmueller et al., 1997; Camous et al., 2011). Properdin con-
centration in plasma is low in comparison to other alternative
pathway components [C3: 1000–1500µg/ml (Kohler and Muller-
Eberhard, 1967); and factor B: 74–286µg/ml] (Oglesby et al.,
1988). Thus, properdin secretion by neutrophils is an important
source for local alternative pathway activity.
The alternative pathway is activated by locally produced prop-
erdin by neutrophils, which in an amplification loop, releases C5,
which further augments neutrophil pro-inflammatory responses
(Camous et al., 2011). The release of anaphylatoxin C5a medi-
ates chemotaxis and degranulation of neutrophils secreting prop-
erdin, implying that neutrophils support the complement acti-
vation system facilitating elimination of various microorganisms
(Schwaeble and Reid, 1999). However, uncontrolled activation of
the alternative pathway via neutrophil secreted properdin could
potentially promote inflammatory responses, which may be harm-
ful for the host (Sylvestre and Ravetch, 1994) leading to diseases
such as vasculitis and rheumatoid arthritis (Schwaeble and Reid,
1999). Properdin, C2, and factor D deposits in the synovium are
also involved in the inflammatory process (Dimitrova et al., 2010).
Mice studies have shown that properdin in the systemic circulation
promotes alternative pathway –mediated injury in arthritis, mak-
ing properdin a possible therapeutic target. Release of properdin
locally by leukocytes at the site of inflammation would activate
the alternative pathway and aggravate tissue injury in the joint
(Kimura et al., 2010).
Properdin secreted by activated neutrophils binds to apoptotic
T cells without activating complement since the concomitant C3b
deposition is not detected on T cells or neutrophils. The granules
of neutrophils secrete properdin, which then binds to apoptotic
cells (Kemper et al., 2008) (Table 2). In addition, both CD4+ and
CD8+ T cells have the potential to produce properdin (Schwae-
ble et al., 1993). Properdin binds to apoptotic T cells and enhances
phagocytosis by macrophages, suggesting that properdin functions
in the recognition via sulfated GAGs and removal of apoptotic
cells (Kemper and Hourcade, 2008; Xu et al., 2008; Ferreira et al.,
2010). Dendritic cells, like macrophages, can also be a source of
complement proteins, i.e., properdin, factor H, factor I, C3, C5,
C9, factor D, and C1q (Reis et al., 2007). Dendritic cells found
in most tissues are important in circumstances where comple-
ment proteins may be at very low concentration, as dendritic cells
play a role in capturing, processing, and presenting antigens to T
lymphocytes.
Endothelial cells, at the inner surface of the blood vessel wall,
express a range of complement proteins. Properdin transcripts are
induced in ECs in response to shear stress, following which prop-
erdin is synthesized and released in extracellular compartments.
Shear stress of 2–3 dyn/cm2 can induce properdin up-regulation
(Bongrazio et al., 2003). Furthermore, changes in the shear stress
could potentially result in local changes in the concentration of
properdin, thus regulating the alternative pathway (Bongrazio
et al., 2003).
Properdin has also been implicated in energy metabolism and
lipid metabolism (Gauvreau et al., 2012). In the properdin gene
deficient mice, properdin deficiency leads to fat storage, decrease
in energy output and the post-prandial triglyceride clearance
delay, compared to the wild-type mice. Thus, properdin could
regulate fatty acid uptake into adipose tissue suggesting that com-
plement may have a dual role in adipose tissue (Gauvreau et al.,
2012).
The alternative pathway and complement proteins may be
involved in the cartilage transformation. The distribution of prop-
erdin on tibia appears in the resting area but not in all cells, and is
also found in the hypertrophic area localized at the cell periphery.
C3, factor B and properdin are observed in the resting zone of
cartilage, indicating synthesis of these proteins by cartilage cells.
Furthermore the presence of these proteins in resting cartilage may
indicate that the alternative pathway could possibly play a role in
the development of this tissue (Andrades et al., 1996).
EXTRAHEPATIC BIOSYNTHESIS OF FACTOR H
The liver is the primary site of factor H production. The liver
expresses two different human factor H mRNA species; the 4.3 kb
(FH) and the 1.8 kb (FHL-1) (Estaller et al., 1990). The 4.3 kb
mRNA is more abundant than the 1.8 kb. The factor H secretion
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Table 3 |Various functions assigned to factor H.
Functions of factor H Reference
Downregulates the alternative pathway. Whaley and Ruddy (1976)
Acts as a cofactor for factor I in the process of conversion of C3b to iC3b
Inhibits the formation of C3 convertases of the alternative pathway by binding to C3b Conrad et al. (1978)
Prevents the interaction of C3b and factor B
Decay acceleration activity: inhibits alternative pathway by dissociating C3 convertases C3bBb and C3bBbC3b Weiler et al. (1976)
Downregulates classical pathway by competing with C1q for binding to activators. Kishore and Sim (2012)
Have roles as adhesion ligands in host-pathogen interactions. Losse et al. (2010)
Neutrophils exhibit a cellular receptor CR3 for factor H, CFHL1, and for ComoloR1 that enhances attachment of
neutrophils to C. albicans
Losse et al. (2010)
by Kupffer cells and hepatocytes is up-regulated by IFN-γ in rats
(Schlaf et al., 2002). The extrahepatic synthesis of factor H in
humans is also up-regulated by IFN-γ (Gasque et al., 1995; Friese
et al., 1999, 2003; Schlaf et al., 2001). Low levels of extrahepatic fac-
tor H expression have been reported in the brain, eyes, lungs, heart,
spleen, kidneys, pancreas, and placenta as well as neurons, and glial
cells (Nawajes et al., 2006). Complement proteins are known to be
expressed in neurons, microglia, astrocytes, and oligodendrocytes
(McGeer and McGeer, 2004). Neurons, which are particularly sus-
ceptible to complement-mediated damage, may be protected by
factor H synthesis against the classical and the alternative pathway
mediated cell damage.
Several components of the alternative pathway are also syn-
thesized in the adipose tissue (Moreno-Navarrete et al., 2010).
Adipocytes express factor H and various other proteins, such as
properdin, C3, factor B, C1q, and C3a-receptor (C3aR). Factor
H gene expression has also been detected in human adipose tis-
sue. Interestingly, circulating factor H corresponded positively
with body mass index (BMI), waist circumference, triglycerides,
and inflammatory parameters, and negatively with insulin sensi-
tivity and high density lipoprotein (HDL) cholesterol (Moreno-
Navarrete et al., 2010). The association between factor H gene
expression and insulin resistance was only found in the omental
fat. Mature adipocytes also showed significant gene expressions of
both factor H and factor B. This increase in circulating factor H and
factor B concentration in subjects with abnormal glucose toler-
ance could reflect the elevated stromovascular cells (SVC)-induced
alternative pathway activation in omental adipose tissue linked to
insulin resistance and metabolic disturbances (Moreno-Navarrete
et al., 2010).
LOCAL SYNTHESIS OF FACTOR H BY DIFFERENT CELL TYPES
Complement synthesis and its regulation have also been exam-
ined in cell lines derived from hepatomas and myelomonocytic
tumors (Perlmutter and Colten, 1986). Additionally, several tumor
cells have been reported to express and release increased amounts
of factor H, possibly to reduce complement activation in their
microenvironment and provide protection from complement
attack (Wurzner et al., 1995; Fedarko et al., 2000; Junnikkala et al.,
2000). Factor H expression is enhanced by IFN-γ in monocytes,
human umbilical vein endothelial cells (HUVEC) and as much as
sixfold in synovial fibroblasts but not by TNF-α (Schwaeble et al.,
1987). The presence of higher levels of factor H induced by IFN-γ
is likely to confer resistance against complement-mediated lysis of
these cells (Ripoche et al., 1988b; Friese et al., 1999). Likewise, ECs
as well as epithelial cells also secrete factor H, which is augmented
by IFN-γ (Ripoche et al., 1988b; Brooimans et al., 1989, 1990).
Mesenchymal stem cells (MSCs) are another type of cell that con-
stitutively produce factor H at the rate of ∼300 ng/106 cells/day.
Factor H produced by MSCs is also increased by IFN-γ as well as
TNF-α (Tu et al., 2010).
Factor H is synthesized by keratinocytes with regulation by
INF-γ (Table 4). Keratinocytes are also reported to produce C3
and factor B as well as cytokines (Pasch et al., 1999). It has been
suggested that keratinocytes would need to produce complement
regulatory proteins as a mechanism to prevent epidermal damage
from autologous complement activation in response to invading
pathogens (Timar et al., 2006).
Factor H, unlike properdin, binds neutrophils via CR3 as well
as CR4 and has been shown to induce neutrophil adherence
and release of reactive oxygen species (ROS) (DiScipio et al.,
1998). Additionally, release of endogenous anti-inflammatory fac-
tor H protects synovial fibroblasts against inflammatory damage
and complement-mediated cell lysis during and at the onset of
rheumatoid arthritis (Friese et al., 2003).
FACTOR H AND PROPERDIN INTERACTION WITH HEPARIN
SULFATE IN PROTEINURIA
Both factor H and properdin bind to different epitopes on heparin
sulfate of proximal tubular epithelial cells. CCP 7 (Clark et al.,
2006), CCP 9 (Ormsby et al., 2006), and CCP 19–20 modules
(Blackmore et al., 1996, 1998) of factor H have been identified as
binding sites for polyanions such as heparin. The alternative path-
way has a significant role in renal diseases. Renal injury may result
from mutations of the complement system. In proteinuria the
complement-mediated tubular injury is a result of complement
factors found in ultrafiltrate which activates the alternative path-
way on tubular cells (Zaferani et al., 2012). Studies on rats showed
factor H in the tissue of normal rat kidney, localized in glomeruli
and interstitium, particularly in the interstitial extracellular matrix
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Table 4 | Extrahepatic sources of factor H.
Sites/source of biosynthesis of factor H Comments/possible implications Reference
Neuronal cells Protects cells from complement-mediated damage which can causes
central nervous system (CNS) injury
McGeer and McGeer (2004)
Endothelial cells Secretes factor H along with epithelial cells. IFN-γ heightens expression Brooimans et al. (1989)
Mesenchymal stem cells Produce factor H constitutively to inhibit complement activity. Regulated
by IFN-γ and TNF-α
Tu et al. (2010)
Adipose tissue Linked to insulin resistance, obesity, and metabolic disorders Moreno-Navarrete et al. (2010)
Keratinocytes Modulated by IFN-γ, to maintain homeostasis in order to prevent
epidermal damage
Timar et al. (2006)
(ECM). During proteinuria, factor H was shown to be localized on
the luminal side of tubuli. In tubular brush borders of proximal
tubuli, factor H is not present whereas factor H was observed to
be localized on the brush borders during proteinuria. Properdin,
on the other hand, is localized on the apical side of tubular cells
during proteinuria where factor H is also co-localized. However, in
some tubuli either properdin or factor H were found to be positive
(Zaferani et al., 2012).
The alternative pathway is activated by properdin on tubular
cells through heparin sulfate interaction, whereas factor H inhibits
the alternative pathway on tubular cells also by binding to heparin
sulfate. Therefore, alternative pathway activation would proceed
when properdin binds only to heparin with low sulfation, thus
up-regulating the alternative pathway. On the other hand, factor
H binds to more highly sulfated heparin isoforms, thus downreg-
ulating the alternative pathway (Zaferani et al., 2012). The filtered
properdin is crucial for complement activation on the tubular
surface in patients with proteinuric renal disease. Thus, inhibiting
properdin binding and subsequent alternative pathway activation
on the tubular cells may have therapeutic value in proteinuric renal
disease (Gaarkeuken et al., 2008).
TYPES OF PROPERDIN DEFICIENCIES
All phenotypes of properdin deficient individuals express mRNA
properdin synthesis by monocytes (Fredrikson et al., 1998). Three
phenotypes for properdin deficiencies have been identified: type
I deficiency (complete deficiency) of properdin is the absence of
properdin and function in plasma; type II (incomplete deficiency)
is characterized by low concentrations of properdin in plasma
which is less than 10% of normal; and type III (dysfunction of
properdin) is the rare type which produces impaired fragment of
properdin (Fijen et al., 1999). These deficiencies have been linked
to the susceptibility to meningococcal disease. Properdin being
expressed by monocytes were observed in type I deficiency and
in type II deficiency with two cases from Swedish and Danish
family (Fredrikson et al., 1998). Thus, in properdin type I defi-
cient individuals,monocytes synthesize no intracellular or secreted
properdin. This might be due to a normal mRNA transcription
and a truncated properdin molecule being synthesized (Fredrik-
son et al., 1998). Conversely, intracellular properdin and secreted
properdin is produced normally in individuals with type II defi-
ciency. In type II deficient individuals, a low level secretion of
properdin by monocytes can take place even in the absence of
cytokine stimulation (Schwaeble et al., 1994).
Properdin deficiency can also lead to functional changes in neu-
trophils and CD4+ T cells (Dimitrova et al., 2010), which prevent
joint alterations and inflammatory processes, suggesting the role
of properdin in immune complex-induced arthritis. A systemic
immune response has been evident in wild-type and properdin
deficient mice. Bone erosion in zymosan induced arthritis model
was seen in wild-type as well as properdin deficient mice that
was localized in bone marrow, cartilage, and bone matrix. In the
wild-type mice, CD4+ T cells were found in all infiltration areas
of joints. However, in properdin deficient mice, infiltration areas
and cartilage were mainly enriched with C5aR positive cells (very
weak staining for CD4 positivity) but decreased synovial levels of
C5a compared to wild-type mice. The abundant C5aR staining
in properdin deficient mice could be localized on synoviocytes
in cartilage, suggesting its contribution in bone degradation. In
addition, macrophages and mast cells in the infiltration region
are likely source of C5aR, promoting joint inflammation via pro-
inflammatory cytokines and mediators. It is possible that over
a period, properdin deficiency leads to infiltration of a range of
effector cells in a hierarchical way leading to proteoglycan loss and
bone erosion (Dimitrova et al., 2010).
HUMAN FACTOR H-ASSOCIATED DISEASES
Mutations or polymorphisms found in factor H heparin binding
sites result in dysfunction of factor H, associated with over acti-
vation of complement causing tissue damage (Clark et al., 2013).
DDD or membranoproliferative glomerulonephritis type II is a
rare renal disease that progresses to end-stage renal failure in about
50% of patients. The disease is associated with uncontrolled alter-
native pathway activation in plasma that generates C3 activation
fragments depositing in the glomeruli (Smith et al., 2007). Sim-
ilarly, C3 activation is uncontrolled in factor H-deficient mice
and the C3 is accumulated at the glomerular basement mem-
brane. DDD has been associated with mutations of factor H
(Dragon-Durey et al., 2004; Licht and Fremeaux-Bacchi, 2009).
These mutations may lead to a quantitative factor H deficiency or
dysfunctional factor H and, thus, an insufficient control on plasma
complement activation (Dragon-Durey et al., 2004). Loss of prop-
erdin also aggravates renal disease linked to the deficiency of factor
H (Ruseva et al., 2012).
Frontiers in Immunology | Molecular Innate Immunity April 2013 | Volume 4 | Article 93 | 8
Kouser et al. Regulatory functions of properdin and factor H
Age-Related Macular Degeneration (AMD) is a leading cause
of visual impairment in elderly, western populations. In recent
years, complement gene mutations and polymorphisms have been
found to be associated with AMD, suggesting that the complement
system is involved in the pathogenesis of the disease (Charbel Issa
et al., 2011). The common factor H polymorphism 402H has been
identified as an important genetic risk factor for developing AMD,
while common polymorphisms in C3 and factor B also contribute
to the disease. In addition, defects of factor H in the RCA at the
surfaces of the Bruch’s membrane in the retina may also result
in AMD (Hageman et al., 2005; Clark et al., 2010; Heurich et al.,
2011). Curiously, properdin has also been screened in patients
with AMD and from the 10 exons sequenced in properdin of
patients with AMD, only four single nucleotide polymorphisms
(SNPs) were identified. However, three SNPs were intermittent
and the fourth SNP of exon 10 is frequent, but not linked with
AMD (Seitsonen et al., 2010). Properdin has also been found to be
expressed in choroidal neovascular membranes of patients with
AMD (Wolf-Schnurrbusch et al., 2009).
Additionally, factor H mutations affect ∼30% of Atypical
Hemolytic Uremic Syndrome (aHUS) patients. More than 100 dif-
ferent factor H mutations have been described in aHUS patients
(Saunders et al., 2006, 2007). Heterozygous mutations have been
described in majority of cases, affecting various domains of fac-
tor H. However, most of the mutations affect CCP 19–20 mod-
ule. Functional analyses of several of these mutants showed an
impaired interaction with C3b, heparin, and ECs (Sánchez-Corral
et al., 2002; Manuelian et al., 2003; Clark et al., 2013). Addition-
ally, anti-factor H IgG autoantibodies, which affect mainly young
patients and children, are detected in ∼10% of aHUS patients
(Józsi et al., 2008). Factor H and low levels of C3 are synthesized
by glomerular mesangial cells. It has been found that IL-1 induces
synthesis of C3, but not factor H. Factor H production is stim-
ulated by IFN-γ in human mesangial cells (van den Dobbelsteen
et al., 1994). These cells are involved in the structure and function
of normal glomerulus (Couser et al., 1985; Lesher et al., 2013).
Low levels of properdin have been detected in renal diseases
due to hypercatabolism. In the glomeruli, deposits of properdin
have been identified in patients with the acute and chronic lupus
nephritis (Ziegler et al., 1975). In glomerular basement membrane,
the presence of properdin granular deposits was identified in DDD
(Kim et al., 1979). This indicates that the loss of properdin is also
involved in the pathogenesis of renal diseases associated with factor
H (Lesher et al., 2013).
CONCLUSION
Further studies into the synthesis of these two complement reg-
ulatory proteins in different tissues and cell types should give
more insight into the role of properdin and factor H as a poten-
tial biomarker for a range of diseases. For example, factor H
has been shown to be elevated in the bronchoalveolar lavage
(BAL) and sputum of lung cancer patients (Pio et al., 2010)
and has also been described as a marker for bladder cancer
(Cheng et al., 2005). Further studies may shed light on the role
of properdin in the pathogenesis of AMD as well as its thera-
peutic involvement. Underpinning the conditions which regulate
enhanced/decreased local synthesis of properdin and factor H by
various cells could help understand the pathogenesis of a range
of diseases. More importantly, both properdin and factor H are
vital complement regulators as well as modulators of cellular
functions. These proteins regulate cellular adhesion, phagocy-
tosis, and antimicrobial activities. The non-complement related
properties of properdin and factor H merit further investigation
in order to understand their homeostatic role in the clearance
of apoptotic cells, modulation of adaptive immunity, resistance
against infections, and cellular interactions with ECM, and tumor
cells.
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